Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (371-380 of 398) with videos related to

Pageof 40
Sort By:
International Journal of Bipolar Disorders|January 3, 2023
A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early interventionA Ratheesh, D Hett, J Ramain, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 6, 2020
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisLaura Obici, John L Berk, Alejandra González-Duarte, et al.
Physical Review Letters|November 13, 2008
Intense geodesic acousticlike modes driven by suprathermal ions in a tokamak plasmaR Nazikian, G Y Fu, M E Austin, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Neurology and Therapy|December 16, 2022
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of EplontersenTeresa Coelho, Márcia Waddington Cruz, Chi-Chao Chao, et al.
European Journal of Neurology|April 29, 2020
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trialT H Brannagan, A K Wang, T Coelho, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2022
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosisTatiana Prokaeva, Tracy Joshi, Elena S Klimtchuk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Pageof 40

Showing results (371-380 of 398) with videos related to

Sort By:
Pageof 40
International Journal of Bipolar Disorders|January 3, 2023
A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early interventionA Ratheesh, D Hett, J Ramain, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 6, 2020
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisLaura Obici, John L Berk, Alejandra González-Duarte, et al.
Physical Review Letters|November 13, 2008
Intense geodesic acousticlike modes driven by suprathermal ions in a tokamak plasmaR Nazikian, G Y Fu, M E Austin, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
Neurology and Therapy|December 16, 2022
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of EplontersenTeresa Coelho, Márcia Waddington Cruz, Chi-Chao Chao, et al.
European Journal of Neurology|April 29, 2020
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trialT H Brannagan, A K Wang, T Coelho, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2022
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosisTatiana Prokaeva, Tracy Joshi, Elena S Klimtchuk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 1, 2018
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialMarcia Waddington-Cruz, Elizabeth J Ackermann, Michael Polydefkis, et al.
Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.
Pageof 40